Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AKBA – Akebia Therapeutics Inc.

Akebia Therapeutics, Inc.
AKBA
$3.72
Name : Akebia Therapeutics, Inc.
Sector : Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Mark. Cap: $975,692,736.00
EPSttm : -0.21
finviz dynamic chart for AKBA
Akebia Therapeutics, Inc.
$3.72
1.78%
$0.065

Float Short %

7.35

Margin Of Safety %

Put/Call OI Ratio

0.16

EPS Next Q Diff

-0.06

EPS Last/This Y

0.28

EPS This/Next Y

0.32

Price

3.65

Target Price

7.4

Analyst Recom

1

Performance Q

89.12

Relative Volume

1.71

Beta

0.88

Ticker: AKBA




19 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-06-02AKBA3.260.190.0442491
2025-06-03AKBA3.420.180.0144618
2025-06-04AKBA3.640.170.1246800
2025-06-05AKBA3.690.170.0449891
2025-06-06AKBA3.960.170.0050199
2025-06-09AKBA3.830.170.0649690
2025-06-10AKBA3.920.170.1550940
2025-06-11AKBA3.560.170.2152863
2025-06-12AKBA3.680.170.0453548
2025-06-13AKBA3.560.170.0653383
2025-06-16AKBA3.590.170.0453519
2025-06-17AKBA3.510.170.0153745
2025-06-18AKBA3.570.170.0154511
2025-06-20AKBA3.680.170.8355178
2025-06-23AKBA3.650.160.3043008
2025-06-24AKBA3.660.160.0143214
2025-06-25AKBA3.680.160.1944490
2025-06-26AKBA3.730.160.0044606
2025-06-27AKBA3.650.160.0644690
DateSymbolLastP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-06-02AKBA3.260.0- -0.09
2025-06-03AKBA3.420.0- -0.09
2025-06-04AKBA3.640.0- -0.09
2025-06-05AKBA3.690.0- -0.09
2025-06-06AKBA3.9637.5- -0.06
2025-06-09AKBA3.8337.5- -0.06
2025-06-10AKBA3.9137.5- -0.06
2025-06-11AKBA3.5637.5- -0.06
2025-06-12AKBA3.6537.5- -0.06
2025-06-13AKBA3.5637.5- -0.06
2025-06-16AKBA3.5937.5- -0.06
2025-06-17AKBA3.5037.5- -0.06
2025-06-18AKBA3.5637.5- -0.06
2025-06-20AKBA3.6837.5- -0.06
2025-06-23AKBA3.6537.5- -0.06
2025-06-24AKBA3.6637.5- -0.06
2025-06-25AKBA3.6837.5- -0.06
2025-06-26AKBA3.7337.5- -0.06
2025-06-27AKBA3.6537.5- -0.06
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-06-02AKBA-3.0149.027.83
2025-06-03AKBA-3.0149.027.83
2025-06-04AKBA-3.0149.027.83
2025-06-05AKBA-3.1349.027.83
2025-06-06AKBA-3.1349.027.83
2025-06-09AKBA-3.1349.257.83
2025-06-11AKBA-3.1349.257.96
2025-06-12AKBA-3.2649.257.96
2025-06-13AKBA-3.2649.257.96
2025-06-16AKBA-3.2649.247.97
2025-06-17AKBA-3.1749.247.97
2025-06-18AKBA-3.1749.247.97
2025-06-19AKBA-3.1749.247.97
2025-06-20AKBA-3.1749.247.97
2025-06-24AKBA-3.1749.267.97
2025-06-25AKBA-3.1749.267.97
2025-06-26AKBA-3.1749.267.35
2025-06-27AKBA-3.1749.267.35
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

0.03

Avg. EPS Est. Current Quarter

-0.03

Avg. EPS Est. Next Quarter

-0.03

Insider Transactions

-3.17

Institutional Transactions

49.26

Beta

0.88

Average Sales Estimate Current Quarter

47

Average Sales Estimate Next Quarter

45

Fair Value

Quality Score

40

Growth Score

50

Sentiment Score

84

Actual DrawDown %

73.4

Max Drawdown 5-Year %

-98.2

Target Price

7.4

P/E

Forward P/E

49.32

PEG

P/S

5.18

P/B

38.85

P/Free Cash Flow

EPS

-0.22

Average EPS Est. Cur. Y​

-0.06

EPS Next Y. (Est.)

0.26

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-24.51

Relative Volume

1.71

Return on Equity vs Sector %

-208.2

Return on Equity vs Industry %

-191.7

EPS 1 7Days Diff

EPS 1 30Days Diff

0.1

EBIT Estimation

Akebia Therapeutics, Inc.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees: 181
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
stock quote shares AKBA – Akebia Therapeutics Inc. Stock Price stock today
news today AKBA – Akebia Therapeutics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AKBA – Akebia Therapeutics Inc. yahoo finance google finance
stock history AKBA – Akebia Therapeutics Inc. invest stock market
stock prices AKBA premarket after hours
ticker AKBA fair value insiders trading